{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selinexor+%28KPT-330%29&page=4", "query": { "intervention": "Selinexor (KPT-330)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 90, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selinexor+%28KPT-330%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Selinexor+%28KPT-330%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T04:20:12.980Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02283359", "title": "Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-12", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-01-15", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02283359" }, { "nct_id": "NCT04898894", "title": "Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage in Relapse", "Acute Myeloid Leukemia, in Relapse", "Refractory Acute Leukemia of Ambiguous Lineage", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "methotrexate/hydrocortisone/cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 37, "start_date": "2021-11-15", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 8, "location_summary": "San Diego, California • Boston, Massachusetts • New York, New York + 5 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04898894" }, { "nct_id": "NCT06239272", "title": "NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adipocytic Neoplasm", "Liposarcoma", "Atypical Fibroxanthoma", "Angiomatoid Fibrous Histiocytoma", "Fibrosarcoma NOS", "Myxofibrosarcoma", "Angiosarcoma", "Osteosarcoma, Extraskeletal", "Dedifferentiated Liposarcoma", "Myxoid Liposarcoma", "Pleomorphic Liposarcoma", "Myxoid Pleomorphic Liposarcoma", "Low Grade Fibromyxoid Sarcoma", "Sclerosing Epithelioid Fibrosarcoma", "Malignant Tenosynovial Giant Cell Tumor of Soft Tissue", "Epithelioid Hemangioendothelioma", "Glomus Tumor", "Inflammatory Leiomyosarcoma", "Leiomyosarcoma", "Ossifying Fibromyxoid Tumor, Malignant", "Myoepithelioma", "Synovial Sarcoma", "Epithelioid Sarcoma", "Perineurioma, Malignant", "Clear Cell Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Granular Cell Tumor, Malignant", "Melanotic Malignant Nerve Sheath Tumor", "Malignant Peripheral Nerve Sheath Tumor", "Perivascular Epithelioid Tumor, Malignant", "Intimal Sarcoma", "Myoepithelial Carcinoma", "Undifferentiated Sarcoma", "Pleomorphic Sarcoma, Undifferentiated", "Round Cell Sarcoma, Undifferentiated", "NTRK-Rearranged Spindle Cell Neoplasm", "Phosphaturic Mesenchymal Tumor, Malignant", "Round Cell Sarcoma", "Well Differentiated Liposarcoma", "Giant Cell Tumor of Soft Parts NOS", "Low Grade Myofibroblastic Sarcoma", "Dermatofibrosarcoma Protuberans, Fibrosarcomatous" ], "interventions": [ { "name": "Surgical resection", "type": "PROCEDURE" }, { "name": "Proton beam radiation therapy", "type": "RADIATION" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 139, "start_date": "2024-03-27", "completion_date": "2037-06", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 7, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Baton Rouge, Louisiana + 4 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06239272" }, { "nct_id": "NCT01986348", "title": "Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2014-03-03", "completion_date": "2020-01-23", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01986348" }, { "nct_id": "NCT04216329", "title": "Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gliosarcoma", "Newly Diagnosed", "Glioblastoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Generic Radiation therapy (RT)", "type": "RADIATION" }, { "name": "Selective serotonin receptor (5-HT3) antagonists", "type": "OTHER" }, { "name": "Olanzapine", "type": "OTHER" }, { "name": "Salt tablets", "type": "DIETARY_SUPPLEMENT" }, { "name": "Anti-diarrheal", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "DIETARY_SUPPLEMENT" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2020-07-07", "completion_date": "2028-07-30", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04216329" }, { "nct_id": "NCT03555422", "title": "Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Matching placebo for selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 263, "start_date": "2018-01-05", "completion_date": "2025-04-03", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 19, "location_summary": "Tucson, Arizona • Palo Alto, California • Tampa, Florida + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Oak Lawn", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03555422" }, { "nct_id": "NCT02199665", "title": "Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma" ], "interventions": [ { "name": "selinexor", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2014-06-12", "completion_date": "2025-10-25", "has_results": false, "last_update_posted_date": "2025-11-03", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02199665" }, { "nct_id": "NCT04768881", "title": "Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Melanoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-05-12", "completion_date": "2023-09-22", "has_results": true, "last_update_posted_date": "2024-08-23", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 13, "location_summary": "Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Plantation", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "North Platte", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04768881" }, { "nct_id": "NCT04782687", "title": "Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Myeloma Multiple", "Kahler Disease", "Myeloma, Plasma Cell", "Myeloma-Multiple", "Myelomatosis", "Plasma Cell Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Dexamethasone Oral", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2021-09-10", "completion_date": "2026-05-31", "has_results": false, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 10, "location_summary": "Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Albany", "state": "New York" }, { "city": "Eugene", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04782687" }, { "nct_id": "NCT02186834", "title": "Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Liposomal doxorubicin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2014-09-23", "completion_date": "2018-03-14", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-10-13T04:20:12.980Z", "location_count": 2, "location_summary": "Tampa, Florida • Detroit, Michigan", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02186834" } ] }